171 related articles for article (PubMed ID: 23041832)
61. Immunohistochemical and ultrastructural characterization of brain tumors in S100beta-v-erbB transgenic rats.
Yokoo H; Tanaka Y; Nobusawa S; Nakazato Y; Ohgaki H
Neuropathology; 2008 Dec; 28(6):591-8. PubMed ID: 18498286
[TBL] [Abstract][Full Text] [Related]
62. Overexpression of mTOR and p(240-244)S6 in IDH1 Wild-Type Human Glioblastomas Is Predictive of Low Survival.
Machado LE; Alvarenga AW; da Silva FF; Roffé M; Begnami MD; Torres LFB; da Cunha IW; Martins VR; Hajj GNM
J Histochem Cytochem; 2018 Jun; 66(6):403-414. PubMed ID: 29328863
[TBL] [Abstract][Full Text] [Related]
63. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
Nobusawa S; Watanabe T; Kleihues P; Ohgaki H
Clin Cancer Res; 2009 Oct; 15(19):6002-7. PubMed ID: 19755387
[TBL] [Abstract][Full Text] [Related]
64. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells.
Bouvier C; Bartoli C; Aguirre-Cruz L; Virard I; Colin C; Fernandez C; Gouvernet J; Figarella-Branger D
J Neurosurg; 2003 Aug; 99(2):344-50. PubMed ID: 12924709
[TBL] [Abstract][Full Text] [Related]
65. Oligodendrocyte lineage transcription factor 2 inhibits the motility of a human glial tumor cell line by activating RhoA.
Tabu K; Ohba Y; Suzuki T; Makino Y; Kimura T; Ohnishi A; Sakai M; Watanabe T; Tanaka S; Sawa H
Mol Cancer Res; 2007 Oct; 5(10):1099-109. PubMed ID: 17951409
[TBL] [Abstract][Full Text] [Related]
66. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
[TBL] [Abstract][Full Text] [Related]
67. Analysis of Olig2 and YKL-40 expression: a clinicopathological/immunohistochemical study for the distinction between subventricular zone II and III glioblastomas.
Batista K; Costa B; Pablo I; Vega IF; Morales J; Alvarez AV; Meilán A; Astudillo A; Alvarez KY
Folia Neuropathol; 2016; 54(1):31-9. PubMed ID: 27179219
[TBL] [Abstract][Full Text] [Related]
68. Oligodendroglial markers in the cuprizone model of CNS de- and remyelination.
Salinas Tejedor L; Gudi V; Kucman V; Pul R; Gingele S; Sühs KW; Stangel M; Skripuletz T
Histol Histopathol; 2015 Dec; 30(12):1455-64. PubMed ID: 26110560
[TBL] [Abstract][Full Text] [Related]
69. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
Mellai M; Piazzi A; Caldera V; Monzeglio O; Cassoni P; Valente G; Schiffer D
J Neurooncol; 2011 Nov; 105(2):345-57. PubMed ID: 21643842
[TBL] [Abstract][Full Text] [Related]
70. IDH1-associated primary glioblastoma in young adults displays differential patterns of tumour and vascular morphology.
Popov S; Jury A; Laxton R; Doey L; Kandasamy N; Al-Sarraj S; Jürgensmeier JM; Jones C
PLoS One; 2013; 8(2):e56328. PubMed ID: 23451042
[TBL] [Abstract][Full Text] [Related]
71. Malignant glioma with primitive neuroectodermal tumor-like component (MG-PNET): novel microarray findings in a pediatric patient.
Liu J; Keisling MP; Samkari A; Halligan G; Pascasio JM; Katsetos CD
Clin Neuropathol; 2016; 35(6):353-367. PubMed ID: 27781423
[TBL] [Abstract][Full Text] [Related]
72. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
[TBL] [Abstract][Full Text] [Related]
73. The definition of primary and secondary glioblastoma.
Ohgaki H; Kleihues P
Clin Cancer Res; 2013 Feb; 19(4):764-72. PubMed ID: 23209033
[TBL] [Abstract][Full Text] [Related]
74. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
75. Immunophenotypic Characterization of Germ Cell Tumor-Derived Primitive Neuroectodermal Tumors: Evidence for Frequent Neuronal and/or Glial Differentiation.
Magers MJ; Perrino CM; Ulbright TM; Idrees MT
Arch Pathol Lab Med; 2021 Aug; 145(8):953-959. PubMed ID: 33290506
[TBL] [Abstract][Full Text] [Related]
76. Increased
Koyasu S; Shimizu Y; Morinibu A; Saga T; Nakamoto Y; Togashi K; Harada H
J Neurooncol; 2019 Dec; 145(3):441-447. PubMed ID: 31667733
[TBL] [Abstract][Full Text] [Related]
77. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V
Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590
[TBL] [Abstract][Full Text] [Related]
78. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
Ohba S; Yamada Y; Murayama K; Sandika E; Sasaki H; Yamada S; Abe M; Hasegawa M; Hirose Y
World Neurosurg; 2019 Jun; 126():e1042-e1049. PubMed ID: 30878754
[TBL] [Abstract][Full Text] [Related]
79. Immunohistochemical expression of Olig2, CD99, and EMA to differentiate oligodendroglial-like neoplasms.
Kurdi M; Eberhart C
Folia Neuropathol; 2021; 59(3):284-290. PubMed ID: 34628794
[TBL] [Abstract][Full Text] [Related]
80. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome.
Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Pierscianek D; Kim YH; Mariani L; Vital A; Ohgaki H
J Neuropathol Exp Neurol; 2012 Aug; 71(8):702-7. PubMed ID: 22805772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
